MGFA has partnered with Bionews to feature the “Myasthenia Gravis News” feed on our MGFA website. We are excited to offer the MG Community this insightful and informative news feed that covers many aspects of living with myasthenia – from research and study results to managing MG, helpful tips, and important news from across the MG World.
Myasthenia Gravis News is a digital platform intended to provide the myasthenia gravis (MG) community with the most recent news and information on MG, as well as first-hand community perspectives from patient and caregiver columnists. All articles on Myasthenia Gravis News are original content produced by in-house writers and editors. Occasionally, BioNews seeks the opinion of outside experts for interviews and Q&As.
Myasthenia Gravis News – The Web’s Daily Resource for Myasthenia Gravis News
- gMG tends to be more aggressive with onset at age 65 or older
by Lila Levinson, PhD on September 18, 2025 at 5:15 pmPeople who begin experiencing symptoms of generalized myasthenia gravis (gMG) at the age of 65 or older tend to have a more aggressive initial disease course — but a more The post gMG tends to be more aggressive with onset at age 65 or older appeared first on Myasthenia Gravis News.
- I’m starting to appreciate how MG seems to love gadgets
by Sarah Bendiff on September 18, 2025 at 2:00 pmI went through a long phase in which I proudly followed a minimalist lifestyle. I was totally against gadgets, especially the small ones that seem unnecessary. Garlic crushers in the The post I’m starting to appreciate how MG seems to love gadgets appeared first on Myasthenia Gravis News.
- Why the act of breathing is a profound gift
by Mark Harrington on September 17, 2025 at 2:00 pmSix years ago, before my myasthenia gravis (MG) diagnosis, I decided that I wanted to be more focused and intentional. To assist with this, I bought an app for my The post Why the act of breathing is a profound gift appeared first on Myasthenia Gravis News.
- Vyvgart may be safe, effective in treatment-resistant MG: Review
by Andrea Lobo on September 16, 2025 at 2:30 pmPeople with refractory myasthenia gravis (MG) who fail to respond to several treatments may be effectively treated with Vyvgart (efgartigimod alfa-fcab), regardless of the type of self-reactive antibodies they carry. The post Vyvgart may be safe, effective in treatment-resistant MG: Review appeared first on Myasthenia Gravis News.
- Registry data back Soliris, Ultomiris as safe, effective for gMG
by Marisa Wexler, MS on September 11, 2025 at 12:00 pmSoliris (eculizumab) and Ultomiris (ravulizumab-cwvz) are generally safe and effective for easing symptoms of generalized myasthenia gravis (gMG) when used in everyday clinical practice. That’s according to data from the The post Registry data back Soliris, Ultomiris as safe, effective for gMG appeared first on Myasthenia Gravis News.
** MGFA Disclaimer – Please read
Myasthenia Gravis Foundation of America (MGFA) and Bionews, Inc. (specifically Myasthenia Gravis News) have entered into a limited agreement that allows for the MGFA to post a link to Myasthenia Gravis News on the myasthenia.org website. Myasthenia Gravis News is a digital platform intended to provide the myasthenia gravis (MG) community with the most recent news and information on MG, as well as first-hand community perspectives from patient and caregiver columnists. All articles on Myasthenia Gravis News are original content produced by in-house writers and editors. Occasionally, Bionews seeks the opinion of outside experts for interviews and Q&As.
The publishing team at Myasthenia Gravis News is made up of science writers and editors, most of whom have PhDs in the life sciences; veteran journalists; and columnists who are members of the MG community. Together, they attempt to ensure that all content published on Myasthenia Gravis News is relevant, accurate, informative, relatable, and easy to understand.
Each piece of content is carefully selected and written by Bionews writers with the MG community in mind. Sources for news stories and resource pages include peer-reviewed studies, press releases, announcements, interviews, webinars, and conference sessions, among others. All articles go through a stringent fact-checking and editing procedure as part of Bionews’ process to ensure they are accurate, objective, comprehensive, and well-explained.
Columns are written by MG patients and caregivers who provide an intimate look at what it’s like to live with the disease. While columns are largely opinion and perspective pieces, each one still goes through a comprehensive editing and fact-checking process by Bionews editors to ensure clarity, accuracy, and fairness.
Myasthenia Gravis News’ site is strictly a news and information website about the disease. It DOES NOT provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The information provided is for educational purposes only and does not substitute for professional medical advice.
The content reflects the unique experiences of the authors and is not necessarily the opinion, views, or recommendations of the MGFA. Medical advisors and clinicians associated with or partnering with the MGFA do not peer review articles and information posted on the Myasthenia Gravis News platform or website. MGFA should not be liable for any information, opinions, articles, advice, guidance, or details posted on the Myasthenia Gravis News site. MGFA has posted this platform as a service to the MG community. Please consult with your doctor and healthcare professionals for specific recommendations and advice pertaining to your healthcare/treatment.